CAMP4 Therapeutics (CAMP) vs Lineage Cell Therapeutics (LCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CAMP4 Therapeutics (CAMP) has outperformed Lineage Cell Therapeutics (LCTX) over the past year, gaining 16.7% versus a loss of 45.2%. CAMP4 Therapeutics is the larger company by market cap ($241.0 million vs $239.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAMP | LCTX |
|---|---|---|
| Share price | $3.84 | $0.9476 |
| Market cap | $240.97M | $239.66M |
| 1-day change | -3.03% | +1.03% |
| YTD return | -37.36% | -43.26% |
| 1-year return | +16.72% | -45.23% |
| 5-year return | — | -59.68% |
| EPS (TTM) | $-2.32 | $-0.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $2.09 |
| 52-week low | $2.86 | $0.88 |
| Distance from 52-week high | -50.45% | -54.66% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +175.26% | +480.41% |
| Average volume | 279.95K | 1.15M |
| Shares outstanding | 62.75M | 252.91M |
| Employees | 48 | 72 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAMP has outperformed LCTX by 61.9 percentage points over the past year.
About CAMP4 Therapeutics
CAMP stock →Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
Healthcare · Biotechnology · 48 employees
About Lineage Cell Therapeutics
LCTX stock →Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.
Healthcare · Biotechnology · 72 employees
CAMP vs LCTX FAQ
Which is bigger, CAMP4 Therapeutics or Lineage Cell Therapeutics?
CAMP4 Therapeutics (CAMP) is larger, with a market capitalization of $240.97M compared with $239.66M for Lineage Cell Therapeutics (LCTX).
Which stock has performed better over the past year, CAMP or LCTX?
CAMP returned +16.72% over the past 12 months, compared with -45.23% for LCTX (price return, excluding dividends). Past performance does not predict future results.
Are CAMP4 Therapeutics and Lineage Cell Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.